喷替酸锌钠 | 11082-38-5

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甘氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 喷替酸锌钠
• 英文名称: Trisodium (N,N-bis(2-(bis(carboxylatomethyl)amino)ethyl)glycinato(5-))zincate(3-)
• 英文别名: trisodium;zinc;2-[bis[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate
• CAS: 11082-38-5
• 化学式: C14H18N3Na3O10Zn
• 分子量: 522.7
• InChiKey: HVASDHJNLYRZEA-UHFFFAOYSA-I

计算性质

• 辛醇/水分配系数(LogP)：
  -18.35
• 重原子数：
  31
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  210
• 氢给体数：
  0
• 氢受体数：
  13

ADMET

代谢

Zn-DTPA在体内经历的代谢变化非常少。

Zn-DTPA undergoes a minimal amount of metabolic change in the body.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

基本治疗：建立专利气道。如有必要，进行吸痰。观察呼吸不足的迹象，如有需要，协助通气。通过非循环呼吸面罩以10至15升/分钟的速度给予氧气。监测肺水肿，如有必要进行治疗……。监测休克，如有必要进行治疗……。预见并处理癫痫发作……。对于眼睛污染，立即用水冲洗眼睛。在运输过程中，用生理盐水连续冲洗每只眼睛……。不要使用催吐剂。对于摄入，如果患者能吞咽、有强烈的干呕反射且不流口水，则用水冲洗口腔，并给予5毫升/千克，最多200毫升的水进行稀释……。在去污后，用干燥的无菌敷料覆盖皮肤烧伤……。/毒药A和B/

Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poison A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

高级治疗：对于无意识、严重肺水肿或呼吸停止的患者，考虑进行口咽或鼻咽气管插管以控制气道。使用气囊面罩装置的正压通气技术可能有益。监测心率和必要时治疗心律失常。 ... 开始静脉输液，使用D5W/SRP：“保持开放”，最低流量/。如果出现低血容量的迹象，使用乳酸钠林格氏液。注意液体过载的迹象。考虑使用药物治疗肺水肿。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象。用地西泮（安定）治疗癫痫。使用丙美卡因氢氯化物协助眼部冲洗。/毒药A和B/

Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in respiratory arrest. Positive pressure ventilation techniques with a bag valve mask device may be beneficial. Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start an IV with D5W /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Watch for signs of fluid overload. Consider drug therapy for pulmonary edema ... . For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poison A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

实验室动物：发育或生殖毒性/ 在怀孕小鼠中进行了生殖研究，剂量高达11.5毫摩尔/千克（根据体表面积[BSA]调整剂量的推荐日剂量1克的31倍），未发现对生育能力或对胎儿有害的证据。平均出生体重略有降低。

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Reproduction studies have been performed in pregnant mice at doses up to 11.5 mmol/kg (31 times the recommended daily dose of 1 gram based on body surface area [BSA] adjusted dose) and have revealed no evidence of impaired fertility or harm to the fetus. There was a slight reduction in the average birth weight.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 特殊风险人群

Zn-DTPA及其放射性螯合物通过肾小球滤过作用被排出。肾功能受损可能会降低它们的消除速率，增加Zn-DTPA的血清半衰期。

Both Zn-DTPA and its radioactive chelates are excreted by glomerular filtration. Impaired renal function may decrease their rates of elimination and increase the serum half- life of Zn-DTPA.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

静脉给药后，Zn-DTPA迅速分布到细胞外液空间。Zn-DTPA没有显著进入红细胞或其他细胞。没有观察到Zn-DTPA在特定器官的积累。肾实质对螯合剂的结合很少或没有。

Following intravenous administration, Zn-DTPA is rapidly distributed throughout the extracellular fluid space. No significant amount of Zn-DTPA penetrates into erythrocytes or other cells. No accumulation of Zn-DTPA in specific organs has been observed. There is little or no binding of the chelating agent by the renal parenchyma.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

Zn-DTPA在胃肠道吸收不良。在动物研究中，口服给药后，吸收率大约为5%。在美国的一项登记研究中，18名患者单次吸入或静脉注射1克剂量的数据显示，吸入产品被吸收，并导致放射性污染物排出量相当。一项对2名人类受试者的研究发现，通过吸入方式给予Ca-DTPA和(14)C-DTPA的吸收率大约为20%。

Zn-DTPA is poorly absorbed in the GI tract. In animal studies, after oral administration, absorption was approximately 5%. In a U.S. Registry of 18 patients who received a single inhaled or intravenous dose of 1 gram, urine data indicate that the inhaled product was absorbed and resulted in a comparable elimination of the radiocontaminant. One study of 2 human subjects that received Ca-DTPA with (14)C-DTPA by inhalation revealed approximately 20% absorption from the lungs.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

Zn-DTPA在给药后的前几个小时内通过肾小球滤过作用经尿液排出体外。尚未有关于肾小管排出的记录。在粪便样本中，只检测到非常少量的放射性(<3%)。

Zn-DTPA is cleared from the plasma in the first few hours after dosing through urinary excretion by glomerular filtration. Renal tubular excretion has not been documented. In stool samples, only a very small amount of radioactivity (<3%) was detected.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

750 kBq的(14)C-DTPA给2名受试者后，获得了血浆滞留和尿液排泄数据。放射性标记的DTPA迅速分布到细胞外液空间，并通过肾小球滤过作用被清除。给药后7小时内，血浆滞留可通过三个指数成分的总和来表示，平均半衰期分别为1.4分钟、14.5分钟和94.4分钟。注射后24小时，血浆中的活性水平低于检测限。在研究期间，没有检测到呼出或随粪便排出的活性。到24小时时，累积尿液排泄量超过注射剂量的99%。/DTPA/

Plasma retention and urinary excretion data were obtained in 2 subjects that received 750 kBq of (14)C-DTPA. ... The radiolabeled DTPA was rapidly distributed throughout the extracellular fluid space and was cleared by glomerular filtration. The plasma retention up to 7 hours post dosing was expressed by the sum of three exponential components with average halflives of 1.4 min, 14.5 min, and 94.4 min. The level of activity in the plasma was below the limit of detection 24 hours after injection. During the study, no detectable activity was exhaled or excreted in the feces. By 24 hours, cumulative urinary excretion was more than 99% of the injected dose. /DTPA/

来源:Hazardous Substances Data Bank (HSDB)